Delix Therapeutics is pioneering a new class of compounds known as neuroplastogens, which aim to revolutionize brain health therapeutics by leveraging the brain's inherent ability to undergo neuroplasticity. This process involves the regrowth and reformation of neural connections, allowing for the potential improvement of mental function in patients suffering from various neuropsychiatric conditions. Delix's neuroplastogen engine focuses on inducing selective neuroplasticity and rewiring specific neural circuits, which can help address prevalent issues such as depression, PTSD, anxiety, and substance use disorders. The company is committed to developing treatments that are safe, fast-acting, and long-lasting, thereby addressing the significant unmet needs in the current landscape of neurological therapies.

The company’s pipeline boasts over 1,500 compounds derived from more than ten unique chemical scaffolds, positioning Delix at the forefront of neurological treatment innovation. Unlike first- and second-generation neuroplastogens, which may have undesirable side effects such as hallucinogenic properties and cardiovascular risks, Delix is focused on creating third-generation neuroplastogens that are non-hallucinogenic and non-cardiotoxic. This approach not only enhances safety but also broadens the potential patient population that can benefit from these therapies. By targeting specific neural circuits and minimizing unwanted effects, Delix aims to provide effective and accessible treatments for individuals with neuropsychiatric and neurodegenerative conditions.

United States

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Delix Therapeutics

Company Details